Ionis Pharmaceuticals, Inc.
MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS

Last updated:

Abstract:

Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Partial Lipodystrophy. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Partial Lipodystrophy in a patient. Further provided herein are methods, compounds, and compositions useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof, associated with Partial Lipodystrophy in a patient.

Status:
Application
Type:

Utility

Filling date:

31 Jul 2019

Issue date:

26 Mar 2020